Introduction
Heart failure (HF) has been associated with increased risk of thrombotic events that affected a third of HF patients. 1 Poor mobility and multiple co-morbidities predispose to occurrence of venous thromboembolism (VTE). 2, 3 The risks are particularly high in patients with acute HF decompensation who require hospital admission with VTE reported in up to half of such patients, unless VTE prophylaxis is given. 2, 3 Many HF patients have background coronary artery disease (CAD) making them prone to coronary thrombosis resulting in myocardial infarction or sudden cardiac death (SCD). 4 Patients with HF are also at increased risk of ischaemic stroke, which has been reported to occur in 2% of such patients within the first year of presentation. 5 In fact, about 20% of patients with ischemic stroke have impaired left ventricular (LV) systolic function. 6 The risk of stroke and systemic VTE is especially high in patients with concomitant atrial fibrillation (AF), which is extremely common in subjects with HF irrespectively of LV ejection fraction ( LVEF). Literature suggests that up to 40% of HF patients may experience the arrhythmia. 7, 8 In patients with HF and preserved LVEF , AF was associated with approximately 3-fold higher risk of ischaemic stroke compared to those with no history of the arrhythmia. 9 In patients with HF with reduced LVEF (HFrEF),the presence of AF carries a 2-fold increased risk of ischaemic stroke and systemic VTE compared to those in normal sinus rhythm (NSR). 10 All major clinical guidelines on management of AF recognise HF as a major risk factor for stroke.
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A retrospective analysis of multicentre trials of cardiac resynchronization therapy in HF demonstrated the presence of AF episodes in a third of patients and it was frequently 'silent'. 13 The study also showed that even short (e.g., 10 min) paroxysms of 'silent' AF might have significant clinical consequences, being associated with 2-fold increased risk of deaths or hospital admission for HF.
The prothrombotic state in heart failure
Congestive HF and AF share a number of common pathophysiological processes producing a multifactorial prothrombotic milieu.
First, both HF and AF are characterized by impaired cardiac and/or systemic haemodynamics predisposing to blood stasis. In AF atrial stasis is caused by lack of synchronous contractility of atrial cardiomyocytes, resulting in absence of efficient atrial systole. The stasis is most prominent within the left atrial (LA) appendage (LAA), which has no 'through flow' and where the blood flow ultimately depends on efficient synchronous contraction of the appendage cardiomyocytes. It is not surprising that the LAA is the most frequent site of thrombus formation in AF; 14 LA dilation has been shown to be independently associated with increased risk for stroke even after adjustment for other recognized stroke risk factors. 15, 16 The right atrial appendage is less prone to thrombus generation as it is smaller and shallower than its left sided counterpart. Intracardiac blood stasis in AF is reflected by increased levels of brain natriuretic peptides despite preserved LVcontractility.
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A C C E P T E D M A N U S C R I P T 18 19 Second, patients with HF have prominent endothelial dysfunction, irrespectively of HF aetiology. 20 The presence of endothelial dysfunction in HF bears increased mortality and risk of hospital re-admissions. Endothelial dysfunction parallels and predisposes to chronic proinflammatory state and increased oxidative stress, which promotes thrombogenesis. 21, 22 Presence of congestive HF further augments endothelial dysfunction already evident in HF. [21] [22] [23] Small areas of endothelial Thrombosis prevention in heart failure with atrial fibrillation
In almost 100,000 patients admitted with HF and enrolled in Get With The
Guidelines-HF programme, AF was independently associated with poor outcome. 27 Current guidelines on management of patients with AF suggest administration of oral anticoagulation in virtually all HF patients without contraindications. 28, 29 Indeed, HF per se puts patents in the category of CHA 2 DS 2 -VASc score ≥1, where oral anticoagulation is advisable with majority of patients having at least one other risk factor thus making oral anticoagulation mandated (i.e., score ≥2). As a result oral anticoagulation should be routinely used in HF with concomitant AF. 31, 32
Anticoagulation with warfarin brings many challenges, given the high inter-and intrapatient variability in INRs, requiring regular anticoagulation monitoring. A high time in therapeutic range (TTR, ie. >70%) is needed to ensure the best outcomes in efficacy and safety [33] [34] [35] ; TTRs can be influenced by multiple clinical risk factors, which have been incorporated into the SAMe-TT 2 R 2 score to help identify those patients who are likely to do well on warfarin [36] [37] [38] .
Real world data indicate that oral anticoagulation in AF is often underutilised, with fear of perceived risk of bleeding complications being the most common reason of not prescribing of the indicated treatment. 26 Although oral anticoagulants should be avoided in patients with genuine high risk of bleeding (e.g., coagulopathy) such patients are uncommon. To avoid inadequate stroke prevention in HF accompanied by
AF, all such patients should have bleeding risk quantification using the recommended HAS-BLED score. 28, 39, 40 In subjects with HAS-BLED score ≥3, risks and benefits of oral anticoagulation should be individually considered and if started the therapy needs to be regularly reviewed to ensure its safety.
Although aspirin is frequently used in patients with HF and NSR, it does not provide adequate protection against stroke or systemic VTE in people with AF. In those few patients where oral anticoagulants are genuinely contraindicated due to high risk of bleeding, aspirin bears similar risk of bleeding to warfarin without providing effective prevention of VTE events; and it should be avoided unless the patient has CAD.
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In view of the profound difference in the risk of stroke and systemic VTE between HF patients with and without AF, should restoration of NSR be the goal in patients with persistent AF? A comparison of the two approaches was performed in the randomised Atrial Fibrillation and Congestive Heart Failure (AF-CHF) study 41 . The trial recruited 1376 patients with LVEF <35% who were followed for an average of 3 years. The study found no difference in rates of stroke between the two groups (p=0.68), although the event rates were low (1% in the rhythm-control group and 2%
in the rate control group).
Several other trials did not find any significant benefit of rhythm control vs. rate control strategy for stroke prevention in AF. Although these studies were not specifically designed for patients with HF, such subjects represented a substantial fraction of their participants. The How to Treat Chronic Atrial Fibrillation (HOT CAFE) study 42 involved patients with mild-moderate HF, but about half of the participants had mild HF with New York Heart Classification (NYHA) class I. In the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study, only 26% of participants had impaired LVEF and 23% of subjects had history of congestive HF (only 9% of all patients had NYHA functional class ≥II, average LVEF was 55%). 43 In the Rate Control versus Electrical Cardioversion for Persistent
Atrial Fibrillation RACE 44 trial with about a half of the 512 participants having a history of symptomatic HF, there was no evidence of superiority of any of the two approaches and adequate rate control may be appropriate for patients with HF.
Thrombosis prevention in heart failure without atrial fibrillation
The pattern of thrombotic complications in HF differs substantially between subjects with and without AF. Whilst cardiogenic stroke and systemic thromboembolism is the major risk in patients with AF, in those without AF risks related to coronary thrombosis dominate. In HF subjects without any history of AF who had NYHA class II-III symptoms, the annual rate of systemic VTE was about 1%, which would correspond to low risk in patients with AF. 45 However the risks may be much higher in selected HF groups, such as those with advanced congested HF with poor mobility. 7, 8 In subanalysis of the Survival and Ventricular Enlargement (SAVE) trial, risk of ischaemic strokes increased by 18% for every 5% reduction in LVEF. 46 In fact, impact of deterioration of left ventricular contractility on VTE risk may be more prominent in HF in NSR than in those with AF; and in the Sudden Cardiac Death-HF (SCD-Heft) study, this association was noted in subjects in NSR only. 47 Patients with severe HF could be more prone to eventually develop AF, which might not be timely reported to clinicians.
Several trials have aimed to establish utility of oral anticoagulants in HF with NSR. [15] [16] [17] In the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) study, patients with impaired left ventricular systolic function (i.e., left ventricular ejection fraction <30%) were randomised for warfarin or antiplatelet therapy. 16 The trial showed a trend towards lower annual rates of non-fatal stroke in the warfarin group (0.7%) compared to aspirin (2.1%) group and lower and similar trend for 
Non-vitamin K oral anticoagulants for use in atrial fibrillation with heart failure
Non-vitamin K oral anticoagulants (NOACs, previously referred to as new or novel oral anticoagulants 49 ) directed to block activity of specific coagulation factors responsible for activation of both intrinsic and extrinsic coagulation pathways have been recently approved for stroke prevention in NVAF (Table 1) .
Whilst showing efficacy, safety and relative convenience compared to warfarin, the NOACs have their own challenges, especially in translating the impressive clinical data to everyday clinical practice [50] [51] [52] .
Apixaban
Apixaban is a selective reversible inhibitor of factor Xa. Its effectiveness and safety in
AF was established in a large Apixaban for the Prevention of Stroke in Subjects With
Atrial Fibrillation (ARISTOTLE) double-blind noninferiority randomised study comparing apixaban (5 mg twice-daily standard dose) with warfarin adjusted to maintain INR 2.0-3.0. 53 (Table 2 ) All trial patients had at least one additional risk factor for stroke. Among 18,201 study participants 35% had HF defined as symptomatic HF or LVEF <40%. This study showed that the risk of stroke and systemic VTE was equal in the two treatment arms, irrespectively of presence of HF (Table 3 ). The presence of HF also did not affect risk of major bleeding, which was similar with both treatments. Bleeding complications annually occurred in 2.2% of
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HF-free patients receiving apixaban, 1.9% of subjects with HF treated with apixaban and 3.1% of patients treated with warfarin (with or without HF).
The ARISTOTLE trial has demonstrated increased risk of the combined end point of stroke, systemic VTE or death in patients with HF who have LVEF < 40% (8.1 per 100 patient-years) compared to 5.32 per 100 patient-years in symptomatic HF with LVEF > 40%, and 1.54 per 100 patient-years in participants with no HF and normal LVEF(p<0.0001 for all comparisons). Despite this apixaban effectiveness was consistent among the three groups. 54 
Rivaroxaban
Rivaroxaban is a factor Xa inhibitor with concentration-dependent anticoagulation effect on oral intake. patients with AF. 55 ; the study included 62.5% of patients with HF. Subjects with HF, as compared to those without HF, more frequently had persistent AF (83% and 78%, respectively) and had higher average CHADS 2 score (3.7 and 3.1, respectively).
Rivaroxaban showed similar effectiveness in people with LVEF < 40% and in those with higher LVEF. The agent maintained equal efficacy and safety profiles among patients with NYHA class III-IV symptoms as in those with more mild HF symptoms.
Of importance, the favourable properties of rivaroxaban were consistent in HF patients with different risk of stroke or systemic VTE. 57 Moreover, when intention to treat analysis was applied to patients with HF, rivaroxaban was not associated with any increase in major or non-major clinically relevant bleeding. warfarin; hazard ratio 0.34, 95% confidence interval 0.14-0.80 for dabigatran 110 mg vs. warfarin).
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Conclusions
Oral anticoagulation is essential in the vast majority of HF patients with AF with nonvitamin K based anticoagulants being suitable alternative to warfarin. In contrast, aspirin alone does not provide adequate stroke prevention in such patients. In HF without AF, oral anticoagulation should not be routinely used, and antiplatelet agents should be prescribed in patients with background CAD. More data on utility of NOACs in HF are awaited with interest.
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